OBJECTIVE: To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria. METHODS:Pregnant women who had recurrence of parasitaemia following 7 days supervised quinine treatment were treated with AL. Serial blood samples were taken over a 7-day period, and pharmacokinetic parameters were estimated. For lumefantrine, these data were compared in a population pharmacokinetic model with data from non-pregnant, mainly male adults with acute malaria. RESULTS: The pregnant women (five in the second trimester and eight in the third trimester) had lower concentrations of artemether, dihydroartemisinin and lumefantrine, and the elimination of lumefantrine in pregnant women was more rapid than reported previously in non-pregnant adults. CONCLUSION: Pregnancy is associated with reduced plasma concentrations of both artemether and lumefantrine. This is likely to be of therapeutic significance as plasma concentrations of lumefantrine, after elimination of artemether, are an important determinant of cure. Further studies are needed to determine the optimum dose regimen of artemether-lumefantrine in pregnancy.
RCT Entities:
OBJECTIVE: To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria. METHODS: Pregnant women who had recurrence of parasitaemia following 7 days supervised quinine treatment were treated with AL. Serial blood samples were taken over a 7-day period, and pharmacokinetic parameters were estimated. For lumefantrine, these data were compared in a population pharmacokinetic model with data from non-pregnant, mainly male adults with acute malaria. RESULTS: The pregnant women (five in the second trimester and eight in the third trimester) had lower concentrations of artemether, dihydroartemisinin and lumefantrine, and the elimination of lumefantrine in pregnant women was more rapid than reported previously in non-pregnant adults. CONCLUSION: Pregnancy is associated with reduced plasma concentrations of both artemether and lumefantrine. This is likely to be of therapeutic significance as plasma concentrations of lumefantrine, after elimination of artemether, are an important determinant of cure. Further studies are needed to determine the optimum dose regimen of artemether-lumefantrine in pregnancy.
Authors: R McGready; J Simpson; S Panyavudhikrai; S Loo; E Mercuri; L Haataja; T Kolatat; F Nosten; L Dubowitz Journal: Ann Trop Paediatr Date: 2000-12
Authors: F Nosten; M Vincenti; J Simpson; P Yei; K L Thwai; A de Vries; T Chongsuphajaisiddhi; N J White Journal: Clin Infect Dis Date: 1999-04 Impact factor: 9.079
Authors: G Lefèvre; S Looareesuwan; S Treeprasertsuk; S Krudsood; U Silachamroon; I Gathmann; R Mull; R Bakshi Journal: Am J Trop Med Hyg Date: 2001 May-Jun Impact factor: 2.345
Authors: R McGready; T Cho; L Villegas; A Brockman; M van Vugt; S Looareesuwan; N J White; F Nosten Journal: Trans R Soc Trop Med Hyg Date: 2001 Nov-Dec Impact factor: 2.184
Authors: A Sowunmi; A M Oduola; O A Ogundahunsi; F A Fehintola; O A Ilesanmi; O O Akinyinka; A O Arowojolu Journal: J Obstet Gynaecol Date: 1998-07 Impact factor: 1.246
Authors: P Teja-Isavadharm; F Nosten; D E Kyle; C Luxemburger; F Ter Kuile; J O Peggins; T G Brewer; N J White Journal: Br J Clin Pharmacol Date: 1996-11 Impact factor: 4.335
Authors: Leena Haataja; Rose McGready; Ratree Arunjerdja; Julie A Simpson; Eugenio Mercuri; François Nosten; Lilly Dubowitz Journal: Ann Trop Paediatr Date: 2002-12
Authors: Paktiya Teja-Isavadharm; James O Peggins; Thomas G Brewer; Nicholas J White; H Kyle Webster; Dennis E Kyle Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Paul Natureeba; Veronica Ades; Flavia Luwedde; Julia Mwesigwa; Albert Plenty; Pius Okong; Edwin D Charlebois; Tamara D Clark; Bridget Nzarubara; Diane V Havlir; Jane Achan; Moses R Kamya; Deborah Cohan; Grant Dorsey Journal: J Infect Dis Date: 2014-06-23 Impact factor: 5.226
Authors: Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten Journal: Antimicrob Agents Chemother Date: 2009-06-29 Impact factor: 5.191
Authors: Sam Salman; Madhu Page-Sharp; Susan Griffin; Kaye Kose; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2011-08-29 Impact factor: 5.191
Authors: Theonest K Mutabingwa; Kandi Muze; Rosalynn Ord; Marnie Briceño; Brian M Greenwood; Chris Drakeley; Christopher J M Whitty Journal: PLoS One Date: 2009-04-08 Impact factor: 3.240
Authors: An-Emmie Nieman; Quirijn de Mast; Meta Roestenberg; Jorien Wiersma; Gheorghe Pop; Anton Stalenhoef; Pierre Druilhe; Robert Sauerwein; André van der Ven Journal: Malar J Date: 2009-12-03 Impact factor: 2.979